Get the Stockscreener App
0.665
7.01%
-0.0501
Pre-market:
.67
0.005
+0.75%
AEON Biopharma Inc. stock is traded at $0.665, with a volume of 46,312.
It is down -7.01% in the last 24 hours and down -7.84% over the past month.
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine. AEON Biopharma, Inc. is based in Irvine, California.
See More
Previous Close:
$0.7151
Open:
$0.735
24h Volume:
46,312
Relative Volume:
0.54
Market Cap:
$17.49M
Revenue:
-
Net Income/Loss:
$-60.11M
P/E Ratio:
-0.153
EPS:
-4.347
Net Cash Flow:
$-12.04M
1W Performance:
-8.86%
1M Performance:
-7.84%
6M Performance:
-23.03%
1Y Performance:
-27.03%
1-Day Range:
$0.6646
$0.7476
1-Week Range:
$0.6646
$0.7476
52-Week Range:
$0.6252
$1.45
AEON Biopharma Inc. Stock (AEON) Company Profile
Name
AEON Biopharma Inc.
Sector
Industry
Phone
(949) 354-6499
Address
5 Park Plaza, Suite 1750, Irvine
Compare AEON vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AEON
AEON Biopharma Inc.
|
0.665 | 17.49M | 0 | -60.11M | -12.04M | -4.347 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
AEON Biopharma Inc. Stock (AEON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-18-23 | Initiated | H.C. Wainwright | Buy |
AEON Biopharma Inc. Stock (AEON) Latest News
AEON Biopharma (AEON) Holds Steady at $0.71 as Stock Consolidates Between Key Support and ResistanceSeasonality Effect - newsline.com
AEON Q4 2025 Earnings: Significant EPS Miss as Pre-Revenue Biotech Faces ChallengesRetail Earnings Report - newsline.com
Number of shareholders of AEON Biopharma, Inc. – AMEX:AEON - TradingView
AEON BIOPHARMA INC (AEON) Stock Chart - ChartMill
AEON Biopharma Presents New Data Supporting Biosimilarity of ABP-450 to BOTOX at AHS 2026 Annual Meeting - Moomoo
AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society - The Manila Times
Botox biosimilar ABP-450 shows similar structure and activity - Stock Titan
AEON Biopharma Presents New Data Supporting Biosimilarity of ABP-450 to BOTOX® at AHS 2026 Annual Meeting - Quiver Quantitative
AEON Technical Analysis | Trend, Signals & Chart Patterns | AEON BIOPHARMA INC (NYSEARCA:AEON) - ChartMill
AEON Biopharma (AEON) Surges 5.6% as Bulls Test Key Resistance at $0.80Factor ETF Flow - newsline.com
AEON Biopharma Edges Higher: Stock Rises 2.75% as it Tests Key ResistanceHigh Conviction Picks - The Legal Advocate
AEON Q4 2025 Earnings: Deep EPS Miss Amid Pre-Revenue StageEPS Miss Report - The Legal Advocate
AEON Biopharma Q4 2025 Earnings: Major EPS Miss and No Revenue Weigh on Investor SentimentEarnings Expansion Phase - Newser
AEON Biopharma Inc. (AEON) Q4 2025 Earnings: Significant EPS Miss and Stock Decline Amid Development ChallengesHigh Growth Earnings - Newser
AEON Biopharma Dips 2.74% as Stock Nears Critical Support at $0.76Watchlist Stock Ideas - Newser
AEON Q4 2025 Earnings: Wider-Than-Expected Loss as Biotech Continues Pre-Revenue PhaseAnalyst Earnings Estimate - newsline.com
12 Health Care Stocks Moving In Monday's Intraday Session - Sahm
AEON Stock Price, Quote & Chart | AEON BIOPHARMA INC (NYSEARCA:AEON) - ChartMill
AEON SEC FilingsAeon Biopharma 10-K, 10-Q, 8-K Forms - Stock Titan
AEON Biopharma shares fall over 2% on quarterly loss - Investing.com
AEON Biopharma shares fall over 2% on quarterly loss By Investing.com - Investing.com South Africa
AEON Biopharma Reports Q1 Financial Results - Intellectia AI
AEON Biopharma Releases Updated Investor Relations Presentation - TipRanks
AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
AEON Biopharma (AEON) releases May 2026 corporate investor presentation via Form 8-K - Stock Titan
AEON Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
AEON Biopharma (NYSE: AEON) Q1 2026 loss, financing deals and going concern risk - Stock Titan
AEON Biopharma (NYSE: AEON) Q1 2026 loss, FDA boosts ABP-450 plan and debt cut - Stock Titan
AEON’s Botox biosimilar plan gets FDA feedback as debt falls 90% - Stock Titan
TradingKey - TradingKey
AEON Biopharma (AEON) details 2026 meeting, director elections and KPMG ratification - Stock Titan
AEON Biopharma Sets Annual Shareholder Meeting - The Manila Times
AEON cites going concern audit note, cash into Q3 2026 - Stock Titan
AEON Biopharma receives additional NYSE American non-compliance notice - MSN
AEON Bio (AEON) Stock: Why Brand Strength (Eye on Rally) 2026-04-20Market Movers - Cổng thông tin điện tử tỉnh Tây Ninh
Migraine Market: Pharma Pipeline Fuels Rapid Expansion by 2034 – DelveInsight | Eli Lilly and Company, Axsome Therapeutics, AEON Biopharma, Charleston Laboratories, Amgen, Teva Pharma, Anne Lindblad - Barchart.com
AEON (AEON Biopharma) PB Ratio : (As of Apr. 10, 2026) - GuruFocus
Form 10-QQuarterly report [Sections 13 or 15(d)] - ADVFN
Weekly Earnings: Will AEON Biopharma Inc be affected by tariffs2026 Big Picture & High Conviction Investment Ideas - baoquankhu1.vn
What is the bull case for AEON Bio (AEON) Stock | AEON Q4 2025 Earnings: AEON Biopharma Inc. misses EPS, no revenue postedAnnual Earnings Summary - newsline.com
Is AEON Bio (AEON) Stock Rebounding | Price at $0.90, Up 1.27%Rip Sell Trade - The Legal Advocate
AEON Biopharma Receives NYSE American Non-Compliance Notice Due to Stockholders’ Equity Deficit and Ongoing Listing Challenges - Minichart
AEON Biopharma Receives Additional NYSE American Noncompliance Notice - The Globe and Mail
AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards - The Manila Times
AEON Biopharma, Inc. (AEON) stock price, news, quote and history - Yahoo Finance Singapore
AEON Biopharma Receives Second NYSE American Notice for Listing Non-Compliance - geneonline.com
AEON (AEON) CFO awarded 754,717 restricted stock units vesting over four years - Stock Titan
AEON Biopharma (AEON) CFO John Bencich files initial insider ownership report - Stock Titan
AEON Biopharma Faces Listing Compliance Risk - Intellectia AI
AEON Biopharma Inc. Stock (AEON) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Cap:
|
Volume (24h):